Octavio Espinoza sold $575K of Ligand Pharmaceuticals Incorporated (LGND)

Executed Mar 4 2025, disclosed Mar 6 2025, 2 days later.

Value, as filed

$575K

5,000 sh × $115.03

Executed

Mar 4 2025

the trade date, as filed

Disclosed

Mar 6 2025

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Octavio Espinoza Chief Financial Officer profile →

Octavio Espinoza (Chief Financial Officer) filed 4 Form 4 reports in the trailing twelve months (0 purchases, 4 sales), most often in Ligand Pharmaceuticals Incorporated (LGND). The largest single filing was $9.2M of LGND (31,641 sh × $292.06, as filed), executed Aug 12.

The name

LGND

Ligand Pharmaceuticals Incorporated LGND · Healthcare · 36 filings in 24 months ticker →

Healthcare · Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Octavio Espinoza in LGND

LGNDSALE Ligand Pharmaceuticals Incorporated $9.2M
31,641 sh × $292.06
Exec Aug 12
Filed Aug 14 · 5:05 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $688K
3,057 sh × $225.00
Exec Mar 11
Filed Mar 13 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $2.8M
13,370 sh across 10 lots
Exec Mar 4
Filed Mar 6 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $340K
1,804 sh × $188.31
Exec Dec 12 2025
Filed Dec 16 2025 · 5:30 PM ET LGNDPURCHASE Ligand Pharmaceuticals Incorporated $104K
1,000 sh × $103.89
Exec May 9 2025
Filed May 13 2025 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $245K
2,104 sh × $116.37
Exec Dec 23 2024
Filed Dec 26 2024 · 5:30 PM ET